Welcome to Shenandoah University's Pharmacogenomics and Personalized Medicine Certificate program, an interactive and easily accessible learning platform for health care providers.
Pharmacogenomics is the study of the role of the genome in drug response. Pharmacogenomics analyzes how the genetic makeup of an individual affects their response to drugs and aims to develop rational means to optimize drug therapy, with respect to the patients' genotype, to ensure maximum efficacy with minimal adverse effects.
Many of us obtained our clinical credentials before the application of pharmacogenomics in personalized medicine became part of healthcare professional training. This certificate program is designed to help you fill in knowledge gaps and to begin applying pharmacogenomics in your practice.
Designed with subject-matter experts at Shenandoah University and the Inova Center for Personalized Medicine, these short modules can be completed separately to earn continuing education credit, or as a complete series to earn a certificate.
Human Genetic Variability: P450 Enzymes & Transporters is designed for mid-career pharmacists, physicians, nurses and other extended healthcare providers. At the completion of this activity, participants should be able to describe the principal routes of elimination of drugs from the body, list the primary functions of phase 1 and phase 2 drug metabolizing enzymes, describe the cytochrome P450 (CYP) classification system and allele designations, discuss the ways in which genetic variation in CYP enzymes can impact drug therapy, list the primary uptake transporters that have clinical relevance, list the primary efflux transporters that have clinical relevance, and describe the primary actions of uptake and efflux transporters in hepatocytes and intestinal epithelial cells.
|Length:||1 hour 30 minutes|
This module covers the role of transport proteins in cellular biology and pharmacotherapy with emphasis on drug pharmacokinetics, drug-drug interactions, and pharmacogenomics. Current and upcoming clinical areas in which transporter pharmacogenomics can support clinical decision making are also discussed.
This module discusses the novel oral anticoagulants (NOACs) with specific subject areas including their comparisons to vitamin K antagonists, basic pharmacology, and pharmacogenomics. Significant emphasis is placed on the current status of research into NOAC pharmacogenomics with respect to what clinicians can expect in the future.